(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 January 2010 (21.01.2010)

PCT

(10) International Publication Number
WO 2010/007046 A3

(51) International Patent Classification:
A61P 3/10 (2006.01) *C07D 403/12* (2006.01)
C07D 277/46 (2006.01) *C07D 249/14* (2006.01)
C07D 213/75 (2006.01) *C07D 417/04* (2006.01)
C07D 231/40 (2006.01) *C07D 417/06* (2006.01)
C07D 401/12 (2006.01) *C07D 471/10* (2006.01)
C07D 413/12 (2006.01) *A61P 3/04* (2006.01)
C07D 417/12 (2006.01) *A61K 31/427* (2006.01)
C07D 417/14 (2006.01)

(21) International Application Number:
PCT/EP2009/058960

(22) International Filing Date:
14 July 2009 (14.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/080,913 15 July 2008 (15.07.2008) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FORSTER, Cornelia, Jutta** [US/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **KWAK, Young-Shin** [KR/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **NAKAJIMA, Katsumasa** [JP/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **WANG, Bing** [US/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) Agent: **VOEGELI-LANGE, Regina**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
22 July 2010

(54) Title: HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS



(I)

(57) Abstract: The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA- diacylglycerol acyl transferase 1 (DGAT1), *e.g.* metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions *etc.* for their treatment.

WO 2010/007046 A3